In 507 adolescents and adults with moderate-to-severe atopic dermatitis responding at week 16, rerandomisation to nemolizumab every 4 or 8 weeks maintained IGA success at week 48 in 61.5% and 60.4% vs 49.7% with withdrawal (placebo); adverse events were similar.
RCTn = 507
Wollenberg et al. Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis